See more : Australian Rare Earths Limited (AR3.AX) Income Statement Analysis – Financial Results
Complete financial analysis of GRN Holding Corporation (GRNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GRN Holding Corporation, a leading company in the Shell Companies industry within the Financial Services sector.
- OptiNose, Inc. (OPTN) Income Statement Analysis – Financial Results
- Red Trail Energy, LLC (REGX) Income Statement Analysis – Financial Results
- ECOPRO MAT (450080.KS) Income Statement Analysis – Financial Results
- Hong Kong Education (Int’l) Investments Limited (1082.HK) Income Statement Analysis – Financial Results
- Landi Renzo S.p.A. (0ND3.L) Income Statement Analysis – Financial Results
GRN Holding Corporation (GRNF)
About GRN Holding Corporation
GRN Holding Corporation does not have significant operations. The company intends to merge with another entity. Previously, it was involved in the gold exploration and development activities. The company was formerly known as Discovery Gold Corporation and changed its name to GRN Holding Corporation in September 2019. GRN Holding Corporation was founded in 2010 and is headquartered in Seattle, Washington.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 28.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.22K | 840.00 | 143.00 | 143.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.22K | 27.96K | -143.00 | -143.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 97.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 467.86K | 125.16K | 1.42K | 0.00 | 1.08M | 100.00K | 10.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.64K | 0.00 |
| SG&A | 53.59K | 9.60K | 2.42K | 1.50K | 467.86K | 125.16K | 1.42K | 1.12K | 1.08M | 95.36K | 10.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 32.38K | 0.00 | 846.00 | 0.00 | 4.91M | -5.26K | 0.00 |
| Operating Expenses | 53.59K | 9.60K | 2.42K | 1.50K | 467.86K | 125.16K | 1.42K | 1.12K | 1.08M | 90.10K | 10.00K |
| Cost & Expenses | 56.80K | 10.44K | 2.57K | 1.64K | 467.86K | 125.16K | 1.42K | 1.12K | 1.08M | 90.10K | 10.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 469.00 | 0.00 | 0.00 | 0.00 | 84.16K | 5.26K | 0.00 |
| Depreciation & Amortization | 3.22K | 840.00 | 143.00 | 143.00 | 467.86K | 125.16K | 1.42K | 52.52K | 4.91M | 0.00 | 0.00 |
| EBITDA | -53.59K | -9.60K | 158.52K | -1.50K | -435.48K | 0.00 | 0.00 | 11.38K | -5.99M | -90.10K | -10.00K |
| EBITDA Ratio | 0.00% | -33.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -56.80K | -10.44K | -2.57K | -1.64K | -467.86K | -125.16K | -1.52K | -1.12K | -5.99M | -90.10K | -10.00K |
| Operating Income Ratio | 0.00% | -36.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.00 | 5.30K | 160.95K | -3.00 | 31.91K | 0.00 | 946.00 | 12.50K | -84.16K | -4.64K | 0.00 |
| Income Before Tax | -56.80K | -5.14K | 158.38K | -1.64K | -435.95K | -125.16K | -575.00 | 11.38K | -6.07M | -100.00K | -10.00K |
| Income Before Tax Ratio | 0.00% | -17.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.00 | -2.00 | -3.00 | -3.00 | 469.00 | -129.16 | -946.00 | -40.01K | 84.16K | 5.26K | 0.00 |
| Net Income | -56.80K | -5.14K | 158.38K | -1.64K | -436.42K | -125.16K | -575.00 | 11.38K | -6.07M | -100.61K | -10.00K |
| Net Income Ratio | 0.00% | -17.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.01 | 0.00 | -0.03 | -0.01 | 0.00 | 0.00 | -1.32 | -0.02 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.01 | 0.00 | -0.03 | -0.01 | 0.00 | 0.00 | -1.32 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 24.88M | 19.12M | 14.00M | 13.30M | 12.49M | 12.39M | 5.71M | 5.38M | 4.59M | 4.19M | 3.75M |
| Weighted Avg Shares Out (Dil) | 24.88M | 19.12M | 14.00M | 13.30M | 12.49M | 12.39M | 5.71M | 5.38M | 4.59M | 4.19M | 3.75M |
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
GRN Holding Corp Announces Joint Venture With One World Legends on Global Distribution of Cannabis
Source: https://incomestatements.info
Category: Stock Reports